Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2013-10-24 Legal Proceedings Report
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
FDAs rådgivande kommitté rekommenderar ett godkännande av Simeprevir för kombinationsbehandling av genotyp 1 kronisk hepatit C hos vuxna
Legal Proceedings Report Classification · 99% confidence The document is a press release dated October 24, 2013, announcing that the FDA's advisory committee recommended the approval of the drug simeprevir for treating Hepatitis C. This type of announcement, detailing a significant regulatory milestone (FDA committee recommendation) and providing context about the drug and the company's outlook, is characteristic of an Earnings Release (ER) or a general regulatory/corporate update. Since it is a specific announcement about a key development rather than a full financial report (10-K, IR) or a transcript (CT), and it focuses on the immediate news, 'ER' (Earnings Release) is the closest fit among the options for a major corporate news announcement, although 'RNS' (Regulatory Filings) is also plausible. Given the structure and content (key announcement, quotes, background on the drug), it functions as a material corporate update, often released alongside or instead of a formal earnings report when major news breaks. However, since it is not explicitly an earnings report summary, and it details a regulatory event, it fits best as a general corporate announcement. Comparing ER (initial announcement of periodical financial results) vs RNS (general regulatory announcements/fallback), this is a specific regulatory event announcement. In many databases, significant non-earnings corporate news like this falls under a general announcement category. Given the options, 'RNS' serves as the best general regulatory/corporate announcement fallback when 'ER' (which usually implies financial results) is not a perfect fit, or 'LTR' if it were a legal proceeding, which it is not. Since it is a press release announcing a major regulatory step, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate general classification for non-standard, material corporate news.
2013-10-24 Swedish
Den regulatoriska processen för Simeprevir i USA
Regulatory Filings Classification · 95% confidence The document is a press release dated October 22, 2013, detailing regulatory updates regarding the drug simeprevir's New Drug Application (NDA) with the US FDA, specifically mentioning an upcoming advisory committee meeting and the expected final decision timeline. This is not a full financial report (like 10-K or IR), nor is it a transcript, management discussion, or dividend notice. It is an announcement concerning regulatory progress and legal/procedural steps related to a drug application. While it touches upon regulatory matters, it is primarily an update on the status of a drug approval process, which often falls under general regulatory announcements or investor relations updates. Given the options, it is a specific regulatory update that doesn't fit the core financial reports or specific corporate actions like DIRS or DIV. Since it is a formal announcement about a regulatory process milestone (FDA committee review), it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-financial, formal announcement, or potentially LTR if the process itself is considered a legal/regulatory proceeding, but RNS is the broader fallback for such updates. Given the context of a press release updating the market on FDA proceedings, RNS is the most appropriate general classification.
2013-10-22 Swedish
The regulatory process for Simeprevir in the U.S.
Regulatory Filings Classification · 95% confidence The document is a press release dated October 22, 2013, detailing the regulatory process for a drug (simeprevir) with the U.S. FDA, specifically mentioning an upcoming advisory committee meeting and expected final decision dates. It is an update on a specific regulatory/legal matter concerning the company's pipeline asset. This fits best under 'Legal Proceedings Report' (LTR) as it concerns regulatory review and potential outcomes, which often involve legal/regulatory scrutiny, or potentially 'Regulatory Filings' (RNS) as a general update. Given the focus on the FDA review process and advisory committee meeting, LTR is a strong candidate, but since it is an update on the *process* rather than a final ruling or lawsuit, and it is a general press release, RNS (Regulatory Filings/General Announcement) is often used for such procedural updates that don't fit the core definitions of ER, IR, or AR. However, since it is a specific update on a regulatory hurdle/review, LTR (Legal Proceedings Report) is often used broadly for significant regulatory actions. Given the options, and that it is a specific update on a regulatory hurdle, I will lean towards RNS as the most appropriate general regulatory announcement fallback, as it is not a formal legal proceeding outcome, but a procedural update. Re-evaluating: The document is a press release providing information about the regulatory status and upcoming steps with the FDA. This is a general corporate update that doesn't fit the specific financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, MANG). It is a regulatory update, but not a formal legal proceeding outcome. Therefore, the fallback 'Regulatory Filings' (RNS) is the most suitable classification for this type of procedural announcement.
2013-10-22 English
Medivir announces data from two phase III studies with Simeprevir in hepatitis C subpopulations – HCV/HIV co-infected and genotype 4 infected patients
Regulatory Filings Classification · 95% confidence The document is titled "Press Release 18 October 2013" and announces preliminary data from Phase III studies regarding the drug Simeprevir for Hepatitis C subpopulations. It details study designs, primary results (SVR12 rates), and provides context about the drug and the disease. This format—a formal announcement of recent clinical trial results, often presented at a conference (EACS)—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release detailing specific, periodic financial/clinical results (though clinical, it drives future earnings), and it is not a full, comprehensive report (like 10-K or IR), the best fit among the options is 'Earnings Release' (ER), as these releases often contain key operational and clinical milestones that impact investor outlook, or 'Regulatory Filings' (RNS) if it were a mandatory filing. Given the content focuses on clinical trial outcomes presented at a conference, it functions as a key operational update, aligning closely with the purpose of an ER, which announces period results/milestones. However, since it is not explicitly quarterly financial results but rather clinical data, and it is a press release, it could also be RNS. Comparing ER (initial announcement of periodical financial results) vs. RNS (general regulatory announcements/fallback), ER is slightly more specific if we interpret clinical trial success as a key performance indicator release. Given the structure and content, it is a high-impact announcement, making ER a strong candidate, but RNS is the safest fallback for non-standard announcements. Since it is a press release announcing key data, and not a formal regulatory filing like a 10-Q/K, I will classify it as an Earnings Release (ER) as it serves the function of communicating key performance indicators/milestones to the market, or RNS. Given the options, ER is often used for press releases detailing significant operational/clinical progress that impacts future earnings. I will lean towards ER as it is a structured announcement of results, even if clinical rather than purely financial.
2013-10-18 English
Medivir meddelar data från två fas III-studier med Simeprevir i hepatit C subpopulationer – HCV/HIV co-infekterade och genotyp 4 infekterade patienter
Legal Proceedings Report Classification · 99% confidence The document is a press release dated October 18, 2013, announcing preliminary data from two Phase III studies of the drug Simeprevir for Hepatitis C subpopulations (HCV/HIV co-infected and genotype 4 infected patients). The content details study designs, primary results (SVR12 levels), safety profiles, and provides context about the drug and the disease. This format—a formal announcement of clinical trial results presented at a conference—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed release of specific, time-sensitive clinical data rather than a summary of overall financial performance (like revenue/EPS), it fits best as an Earnings Release (ER) which often includes operational/clinical milestones, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release detailing results, ER is the closest fit among the options for reporting key operational/clinical achievements. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a simple Dividend Notice (DIV). Given the focus on presenting new clinical data, ER is the most appropriate classification for a major operational/clinical update announcement.
2013-10-18 Swedish
Medivirs valberedning tillsatt
AGM Information Classification · 95% confidence The document is a press release dated October 14, 2013, announcing that the Nomination Committee (valberedning) for Medivir AB has been appointed ahead of the 2014 Annual General Meeting (årsstämman 2014). The text details the composition of this committee, which is responsible for nominating board members and auditors. This type of announcement, concerning the composition or process related to the Annual General Meeting (AGM) or shareholder voting bodies, aligns most closely with the 'AGM Information' category, although it is an announcement about the committee rather than the meeting materials themselves. Given the options, AGM-R is the most appropriate fit as it relates directly to the AGM process.
2013-10-14 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.